Latest Research and Development in the Axillary Hyperhidrosis Market | Key Companies- Allergan, Dermira, and Others

The Axillary Hyperhidrosis market report provides current treatment practices, emerging drugs, Axillary Hyperhidrosis market share of the individual therapies, current and forecasted Axillary Hyperhidrosis market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Axillary Hyperhidrosis treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Axillary Hyperhidrosis market.

Recent Developmental Activities in the Axillary Hyperhidrosis Treatment Landscape

• In September 2022, Botanix Pharma submitted a New Drug Application to the FDA for approval of Sofpironium Bromide for the treatment of severe primary axillary hyperhidrosis (excessive underarmsweating). Phase III studies of Sofpironium Bromide showed very high statistical significance for the treatment of primary axillary hyperhidrosis. Initially it was being developed by Brickell Biotech. But later Botanix acquired all assets primarily related to sofpironium bromide from Brickell.

• In September 2020, Brickell Biotech in collaboration with Kaken, received regulatory approval in Japan to manufacture and market sofpironiumbromide gel, 5% (brand name: ECCLOCK) for the once-daily treatment of primary axillary hyperhidrosis.

• Tapinarof is as a novel small molecule therapeutic aryl hydrocarbon receptor modulating agent topical cream. Studies of the muscarinic antagonist, oxybutynin, have shown efficacy in hyperhidrosis, but it is seldom used due to poor patient tolerance, most commonly dry mouth. As per the companies pipeline, drug is being investigated for Primary Focal Hyperhidrosis.

To Know in detail about the Axillary Hyperhidrosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Axillary Hyperhidrosis Market Insights- https://www.delveinsight.com/sample-request/axillary-hyperhidrosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Axillary Hyperhidrosis Overview
Axillary Hyperhidrosis (AH), a form of excessive sweating from armpits, is a disease that affects the social and occupational lives of many people on all continents. Axillary hyperhidrosis begins during the teenage years and equally affects men and women.

Key Takeaways from the Axillary Hyperhidrosis Market Report

• The Axillary Hyperhidrosis market size is anticipated to grow with a significant CAGR during the study period (2019-2032)

• Total diagnosed prevalent population of Axillary Hyperhidrosis (AH) in the US was approximately 3,301,288 in 2021

• According to the study of Murota et al., the prevalence of primary axillary hyperhidrosis in Japan is 5.75% (males, 6.60%; females, 4.72%) in the population aged 5-64 years

• The leading Axillary Hyperhidrosis Companies include Botanix Pharma, Dermavant Science, TheraVida, GSK, Allergan, and others

• Promising Axillary Hyperhidrosis Pipeline Therapies include Sofpironium bromide (BBI-4000), Tapinarof, Botulinum Toxin Type A, Glycopyrronium Topical Wipes, Meditoxin, GSK1358820, WO3970, and others.

Axillary Hyperhidrosis Epidemiology Segmentation in the 7MM

• Total Axillary Hyperhidrosis Prevalence

• Prevalent Cases of Axillary Hyperhidrosis by severity

• Axillary Hyperhidrosis Gender-specific Prevalence

• Axillary Hyperhidrosis Diagnosed Cases of Episodic and Chronic

Download the report to understand which factors are driving Axillary Hyperhidrosis epidemiology trends @ Axillary Hyperhidrosis Epidemiological Insights- https://www.delveinsight.com/sample-request/axillary-hyperhidrosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Axillary Hyperhidrosis Treatment Market

• First-line treatment: Topical antiperspirants and Qbrexza are considered as first-line treatment of primary axillaryhyperhidrosis. Patients with primary axillary hyperhidrosis often use nonprescription products such aszirconiumsalts. Patients with severe disease may opt for botulin toxin injections.

• Second-line treatment: Botox treatment is considered a second-line treatment in patients who do not respond totopical medications. Further, oral pharmacological agents such as anticholinergics, beta-blockers, andbenzodiazepines are also considered. Anticholinergics work quickly, with most individuals seeing some improvementwithin a week of starting. Limitations of their use include large dose adjustments and subsequent adverse effects(AEs), such as xerostomia, blurred vision, sedation, and urinary retention.

Axillary Hyperhidrosis Emerging Therapy Assessment
Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Key players, such as Brickell Biotech/Kaken Pharmaceutical, Dermavant Sciences/TheraVida, etc., are developing therapies for the treatment of Axillary Hyperhidrosis.

Find out more about the Axillary Hyperhidrosis Pipeline Segmentation, Therapeutics Assessment, and Axillary Hyperhidrosis Emerging Drugs @ Axillary Hyperhidrosis Treatment Landscape- https://www.delveinsight.com/sample-request/axillary-hyperhidrosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Axillary Hyperhidrosis Market Report

• Coverage- 7MM

• Axillary Hyperhidrosis Companies- Botanix Pharma, Dermavant Science, TheraVida, GSK, Allergan, and others

• Axillary Hyperhidrosis Pipeline Therapies- Sofpironium bromide (BBI-4000), Tapinarof, Botulinum Toxin Type A, Glycopyrronium Topical Wipes, Meditoxin, GSK1358820, WO3970, and others.

• Axillary Hyperhidrosis Market Dynamics: Axillary Hyperhidrosis Market Drivers and Barriers

• Axillary Hyperhidrosis Market Access and Reimbursement, Unmet Needs, Emerging Therapies

Dive deep into rich insights for drugs for Axillary Hyperhidrosis Pipeline Companies and Therapies, click here @ Axillary Hyperhidrosis Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/axillary-hyperhidrosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Key Insights
2. Executive Summary of Axillary Hyperhidrosis
3. Competitive Intelligence Analysis for Axillary Hyperhidrosis
4. Axillary Hyperhidrosis: Market Overview at a Glance
5. Axillary Hyperhidrosis: Disease Background and Overview
6. Patient Journey
7. Axillary Hyperhidrosis Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Axillary Hyperhidrosis Unmet Needs
10. Key Endpoints of Axillary Hyperhidrosis Treatment
11. Axillary Hyperhidrosis Marketed Products
12. Axillary Hyperhidrosis Emerging Therapies
13. Axillary Hyperhidrosis: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Axillary Hyperhidrosis
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

Got Queries? Find out the related information on Axillary Hyperhidrosis Mergers and acquisitions, Axillary Hyperhidrosis Licensing Activities @ Axillary Hyperhidrosis Recent Trends, and Future Perspectives- https://www.delveinsight.com/sample-request/axillary-hyperhidrosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.